Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.64 |
| ▸ | FLT4 | P35916 | 1/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | TEK | Q02763 | 1/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623692 | 1.00 | EGFR (0.77) | EGFRERBB2KDREPHB4AURKA | |
| SCHEMBL1447161 | 0.99 | EGFR (0.78) | EGFRERBB2KDREPHB4AURKA | |
| SCHEMBL1446182 | 0.93 | EGFR (0.83) | EGFRERBB2KDREPHB4AURKA | |
| SCHEMBL1920505 | 0.93 | ERBB2 (0.75) | EGFRERBB2 | |
| SCHEMBL1446518 | 0.93 | EGFR (0.70) | EGFRERBB2KDREPHB4AURKA | |
| SCHEMBL185479 | 0.92 | EGFR (0.74) | EGFRERBB2KDREPHB4AURKA | |
| SCHEMBL29623589 | 0.92 | EGFR (0.74) | EGFRERBB2KDREPHB4AURKA | |
| SCHEMBL12743511 | 0.92 | FBP1 (0.65) | EGFRERBB2FBP1 | |
| SCHEMBL12743515 | 0.92 | EGFR (0.68) | EGFRERBB2 | |
| SCHEMBL1333601 | 0.91 | EGFR (0.80) | EGFRERBB2KDREPHB4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025641-A1 | COMBINATIONS OF AN ERK INHIBITOR AND AN EGFR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| US-20120329795-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2012-12-27 | — | — | US | claimed |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| EP-1682147-B1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM INT (DE) | 2009-10-07 | — | — | EP | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| US-20080096881-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| EP-1682147-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| EP-1667992-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2006-06-14 | — | — | EP | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| WO-2005065687-A1 | NOVEL PHARMACEUTICAL COMBINATIONS CONTAINING SCOPINE OR TROPIC ACID ESTERS AND EGFR-KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | claimed |
| WO-2005041973-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20050096332-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-05 | — | — | US | claimed |
| WO-2005028469-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, GRK5, PRKCH | EGFR 63/4885ERBB2 27/4885KDR 604/4885 |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885KDR 688/4885 |
| US-20120329795-A1 | QUINAZOLINE DERIVATIVES | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDR 41/4885 |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | EGFR, ERBB4, GRK5 | EGFR 1/4885ERBB2 7/4885KDR 838/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | EGFR 53/4885ERBB2 29/4885KDR 436/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | EGFR 3691/4885ERBB2 2317/4885KDR 4444/4885 |
| US-20080096881-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDR 55/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | EGFR 53/4885ERBB2 29/4885KDR 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.